News >

Isatuximab Triplet Improves PFS in Relapsed/Refractory Myeloma

Gina Columbus @ginacolumbusonc
Published: Tuesday, Feb 05, 2019

John Reed, MD, PhD

John Reed, MD, PhD

Isatuximab in combination with pomalidomide (Pomalyst) and low-dose dexamethasone was shown to prolong progression-free survival (PFS) compared with pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma, meeting the primary endpoint of the phase III ICARIA-MM trial (NCT02990338).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication